Patent intelligence · US
US 8815226
Protein-polymer-drug conjugates
Protein-polymer-drug conjugates
Patent details — US 8815226
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 26, 2014
- Expiration
- Aug 21, 2034
- Applicant
- Mersana Therapeutics, Inc.
- Claims
- 8
- CPC classes
- A61K, A61K47/58, A61K47/59, A61K47/60
Quick answer
US 8815226 (Protein-polymer-drug conjugates) is held by Mersana Therapeutics, Inc.. Status: granted. Granted Aug 26, 2014. Expires Aug 21, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Mersana Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K47/58, A61K47/59, A61K47/60, A61K47/64, A61K47/6883
More from Mersana Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12427199
Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
granted -
US 12409213
Live attenuated oral vaccine against shigellosis and typhoid fever
granted -
US 12246059
Stable hybrid FC fusion G-CSF formulation
granted -
US 12171822
Infectious plasmodium sporozoites grown in vitro
granted -
US 12156870
Antibody drug conjugates comprising sting agonists
granted -
US 12129288
Polynucleotides heterodimers of soluble interferon receptors and uses thereof
granted -
US 12077543
P2X3 and/or P2X2/3 compounds and methods
granted -
US 11987628
Methods and compositions for modulating CAR-T activity
granted
Frequently asked questions
What is US patent 8815226?
US 8815226 (Protein-polymer-drug conjugates) is held by Mersana Therapeutics, Inc.. Status: granted. Granted Aug 26, 2014. Expires Aug 21, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8815226?
Mersana Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 136 pharmaceutical patents for this assignee.
When does US 8815226 expire?
Our index shows an expiration date of Aug 21, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.